OncoMatch/Clinical Trials/NCT06112704
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Is NCT06112704 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HS-20093 for advanced solid tumor.
Treatment: HS-20093 — HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7-H3 targeted therapy
Previous or current treatment with B7-H3 targeted therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: investigational agent
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: anticancer drug
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: monoclonal antibody
Exception: within 28 days prior to the first scheduled dose of HS-20093
Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
Cannot have received: radiation therapy
Exception: local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Cannot have received: surgery
Exception: major surgery within 4 weeks prior to the first scheduled dose of HS-20093
Major surgery within 4 weeks prior to the first scheduled dose of HS-20093
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ dysfunction [excluded]
Kidney function
Inadequate bone marrow reserve or organ dysfunction [excluded]
Liver function
Inadequate bone marrow reserve or organ dysfunction [excluded]
Cardiac function
Evidence of cardiovascular risk [excluded]
Inadequate bone marrow reserve or organ dysfunction. Evidence of cardiovascular risk
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify